3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025

Zacks12-27 02:07

The biotech sector witnessed a see-saw performance in 2024. Though the year started on a positive note, those gains were erased in the second half due to disappointing third-quarter results, guidance ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2494489498?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-27 02:07","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2494489498","market":"us","top_or_hot":-1,"title":"3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025","media":"Zacks","content":"<div>\n<p>The biotech sector witnessed a see-saw performance in 2024. Though the year started on a positive note, those gains were erased in the second half due to disappointing third-quarter results, guidance ...</p>\n\n<a href=\"https://finance.yahoo.com/news/3-beaten-down-biotech-stocks-180700940.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-27 02:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/3-beaten-down-biotech-stocks-180700940.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The biotech sector witnessed a see-saw performance in 2024. Though the year started on a positive note, those gains were erased in the second half due to disappointing third-quarter results, guidance ...</p>\n\n<a href=\"https://finance.yahoo.com/news/3-beaten-down-biotech-stocks-180700940.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://finance.yahoo.com/news/3-beaten-down-biotech-stocks-180700940.html","article_id":"2494489498","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2494489498","pubTimestamp":1735236420,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"The biotech sector witnessed a see-saw performance in 2024. Though the year started on a positive note, those gains were erased in the second half due to disappointing third-quarter results, guidance cuts, pipeline setbacks and the appointment of vaccine skeptic Robert F. Kennedy Jr. as the head of Health and Human Services.Despite these setbacks, the sector continued to attract investors’ attention due to demand for innovative medicines, especially in areas with great commercial potential, like obesity, immunology and gene therapy. New drug approvals, pipeline progress and an increase in M&A activity were some of the positives in the sector in 2024.Here, we discuss three drug/biotech stocks that took a beating in 2024 but are likely to bounce back in 2025 based on anticipated regulatory approvals and/or positive pipeline updates. These are Immunocore Holdings IMCR, Allogene Therapeutics ALLO and Day One Biopharmaceuticals DAWN.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4539":"次新股","BK4080":"零售业房地产投资信托","IMCR":"Immunocore Holdings plc","ADC":"艾格里房产","DAWN":"Day One Biopharmaceuticals Inc.","BK4231":"零售房地产信托","ALLO":"Allogene Therapeutics Inc.","BK4505":"高瓴资本持仓"},"translate_title":"2025年值得买入3只遭受重创的生物科技股以实现扭亏为盈","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADC":1,"ALLO":1,"IMCR":1,"DAWN":0.9},"content_text":"The biotech sector witnessed a see-saw performance in 2024. Though the year started on a positive note, those gains were erased in the second half due to disappointing third-quarter results, guidance cuts, pipeline setbacks and the appointment of vaccine skeptic Robert F. Kennedy Jr. as the head of Health and Human Services.\nDespite these setbacks, the sector continued to attract investors’ attention due to demand for innovative medicines, especially in areas with great commercial potential, like obesity, immunology and gene therapy. New drug approvals, pipeline progress and an increase in M&A activity were some of the positives in the sector in 2024.\nHere, we discuss three drug/biotech stocks that took a beating in 2024 but are likely to bounce back in 2025 based on anticipated regulatory approvals and/or positive pipeline updates. These are Immunocore Holdings IMCR, Allogene Therapeutics ALLO and Day One Biopharmaceuticals DAWN.\nImmunocore Holdings\nIMCR is a commercial-stage biotech focused on developing a novel class of TCR bispecific immunotherapies called ImmTAX targeting a broad range of diseases, which include cancer, autoimmune and infectious diseases. Kimmtrak, the sole-marketed drug in the company’s portfolio, is the first FDA-approved immunotherapy for metastatic uveal (ocular) melanoma, a rare form of cancer. In the first nine months of 2024, sales of the drug rose 32% year over year to $226 million, driven by increased demand.\nDespite the encouraging top-line growth, the stock has plummeted 58% year to date. This downside can be attributed to investor-perceived risks in pipeline development. The most advanced candidate in Immunocore’s pipeline is brenetafusp, which is being evaluated across two separate clinical studies – a late-stage study for cutaneous melanoma and a phase I/II study for multiple solid tumors, including ovarian, non-small cell lung cancer (NSCLC), and endometrial carcinoma.\nSeveral Wall Street analysts have expressed concerns over brenetafusp’s efficacy beyond cutaneous cancer, given the company’s delay in reporting results from the NSCLC cohort of the phase I/II study. Some analysts also stated that the company’s data on the drug in cutaneous melanoma (reported earlier this year) was ‘underwhelming’.\nThe stock is anticipated to experience a major upside in early 2025 as Wall Street expects IMCR to provide a positive update on the early-stage study of an investigational HIV therapy. The company is also evaluating Kimmtrak in two separate late-stage studies — one as a second or later-line treatment for cutaneous melanoma and another as an adjuvant treatment for uveal melanoma. It is also moving multiple oncology candidates to clinical development. Earlier this month, management started dosing patients in two separate early-stage studies on IMC-R117C and IMC-P115C across advanced gastrointestinal cancer and advanced solid tumors, respectively.\n\nImmunocore Holdings PLC Sponsored ADR Price\n\nImmunocore Holdings PLC Sponsored ADR price | Immunocore Holdings PLC Sponsored ADR Quote\n\nIMCR currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.\nLoss per share estimates for 2025 have improved from $2.33 to $1.57 in the past 60 days.\nAllogene Therapeutics\nALLO is developing allogeneic CAR T therapies for treating cancer, especially hematologic indications with high unmet needs. Shares of Allogene have lost 35% year to date due to the strategic changes in Allogene’s pipeline, announced at the start of this year. Based on this change, management decided to upgrade the development of its lead pipeline drug cema-cel from being a third-line therapy in large B cell lymphoma (LBCL) patients to a frontline therapy.\nThough the pivot does expand management’s target market to a wider patient population, investors took the news with a grain of salt since it delayed the company’s initial plans to bring the product to market by at least a couple of years. A regulatory submission to the FDA for the drug is now expected in 2027.\nApart from cema-cel, Allogene is also developing engineered allogeneic CAR-T cell therapy candidates for multiple myeloma and renal cell carcinoma in separate phase I studies. Management is also planning to explore the potential of allogeneic CAR-T cell therapies in autoimmune diseases and start an early-stage study with a new candidate in lupus/systemic lupus erythematosus indication by first-quarter 2025.\n\nAllogene Therapeutics, Inc. Price\n\nAllogene Therapeutics, Inc. price | Allogene Therapeutics, Inc. Quote\n\nAllogene currently carries a Zacks Rank #2 (Buy). Loss per share estimates for 2025 have improved from $1.45 to $1.34 in the past 60 days.\nDay One Biopharmaceuticals\nA commercial-stage biotech, Day One is focused on developing therapies targeting pediatric cancer. Currently, DAWN has only one marketed drug in its portfolio, Ojemda, which received the FDA’s accelerated approval in April for children aged six months and above with relapsed or refractory BRAF-altered pediatric low-grade glioma (pLGG). Commercially launched in the second quarter, the drug has generated more than $28 million in product revenues in the first nine months of 2024.\nOjemda’s approval was a milestone for Day One as it marked the company’s first approval for a marketed drug. The drug is currently the only systemic therapy for pLGG in the country and requires once-weekly administration, with or without food, as a tablet or oral suspension. The ex-U.S. rights of the drug have been out-licensed to Ipsen as part of a licensing deal signed in July.\nDAWN is also evaluating Ojemda in the pivotal late-stage FIREFLY-2 study as a front-line therapy for pLGG patients aged six months to 25 years. The potential success of this study could further expand the drug's eligible patient population. In addition to Ojemda, the company’s pipeline also consists of two other investigational candidates — the recently acquired antibody-drug conjugate (ADC) drug DAY301 and a MEK 1/2 inhibitor pimasertib. Day One aims to dose the first patient in the phase I study on DAY301 to treat solid tumors by early 2025.\nYear to date, shares of Day One Biopharmaceuticals have lost over 13%.\n\nDay One Biopharmaceuticals, Inc. Price\n\nDay One Biopharmaceuticals, Inc. price | Day One Biopharmaceuticals, Inc. Quote\n\nDAWN currently carries a Zacks Rank #2. Loss per share estimates for 2025 have improved from $2.03 to 99 cents in the past 60 days.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nAllogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report\nImmunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report\nDay One Biopharmaceuticals, Inc. (DAWN) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2494489498"}